The Dermatology Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter dermatology partnering deals

The Sensory Organ Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter sensory organ partnering deals.

Partnering in the last decade has seen an increase in dermatology with an rise specifically in modern diagnostic technologies.

Dermatology is the collective term used to describe the study of diseases that affect the skin, hair and nails.

Japan’s big pharma, Astellas, looks to sell dermatology assets according to pharma rumor mill sources.

Following Takeda’s acquisition of Nycomed, its US dermatology subsidiary has announced it will become an independent entity.

Several companies are rumored to be competing to acquire Omega Pharma, the fastest growing consumer healthcare company in the U.K. and Ireland.

By Steve Poile                                     With 110 deals announced, the second quarter continued on from the strong start for life science M&A during 2014.

The 2014 top 50 Pharma company list is out, with an interesting number of movers and shakers By Alamelu Elango

Sun Pharmaceutical has announced 6 M&A deals since 2009.

Valeant Pharmaceuticals is a top pharmaceutical company based in Montreal, Quebec, Canada

This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in May 2014.

Valeant Canada has completed the acquisition of Valeo Pharma’s dermatology product portfolio and several specialty products.

Valeant Pharmaceuticals International has entered into an agreement with Nestle to sell all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash.

Dermira has raised $35 million of new funding in a Series B financing and related transaction

Sandoz has completed its USD 1.525 billion M&A of specialty US dermatology company Fougera Pharmaceuticals on a cash and debt free basis

Top pharma company, Novartis is buying specialty dermatology generics firm Fougera Pharmaceuticals for $1.525 billion in cash

Dermatology drugs aren’t growing fast enough. At least not in Sanofi-Aventis’ opinion…

Los Angeles-based Kythera Biopharmaceuticals has landed a $373 million licensing deal with Bayer Healthcare’s dermatology unit Intendis. The group gets rights to Kythera’s lead product candidate, ATX-101, outside the U.S. and Canada.

Both Desonate(R) and NeoBenz(R) Micro are currently marketed in the U.S. by SkinMedica, Inc. Under the transaction, which is still subject to the necessary regulatory approvals, Intendis will acquire all commercial rights, including assigned contracts and intellectual property related to the two product lines. The deal is expected to close in the Fall of 2009.

Cosmederm Bioscience has announced that UK-based Woodford Investment Management is investing $50 million financing into Cosmederm Bioscience.

UCB and Dermira have entered into an exclusive pharma licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology.